New Data Show MIV Therapeutics’ Vestasync Drug-Eluting Stent Produces Less Fibrinoid and Equivalent Efficacy

MIV Therapeutics, Inc., a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announces that new data from a previously presented animal study comparing the safety and efficacy of the company’s Vestasync hydroxyapatite (HAp) coronary stent coating with low-dose Sirolimus to the Cypher Stent showed less fibrinoid, a marker for delayed healing and equivalent efficacy.
CNN Money